An observational study in Supraventricular Tachycardia (SVT) and Congenital Heart Disease (CHD), sponsored by Stereotaxis. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-10.
Sponsored by Stereotaxis · Observational
The goal of this observational study is to collect real world performance and to confirm the effectiveness and safety of the MAGiC Ablation Catheter for the treatment of supraventricular tachycardia in adult patients with congenital heart disease:
To estimate the rate of acute procedural success and to estimate the rate of chronic success through 6 months post procrdure.
Participants will be asked to have a cardiac ablation procedure and visit their doctor at 1 week, 1 month and 6 monhs post procedure.
The MAGiC-CHD Post-Approval Study is a prospective, non-randomized, multi-center, single-arm study to confirm the effectiveness and safety of the MAGiC Ablation Catheter for the treatment of supraventricular tachycardia (SVT) in adult patients with congenital heart disease (CHD) and limited vascular access or difficult access to the target cardiac chamber.
73 studies on the registry are indexed under Tachycardia, Supraventricular; 22 are open to participants now.
This study's planned enrollment of 40 is below the median of 87 across 28 observational studies indexed under Tachycardia, Supraventricular.
Browse Tachycardia, Supraventricular studies →Stereotaxis is the lead sponsor of 11 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Any patients requiring an ablation procrdure for the treatment of SVT with CHD where there is limited vascular ascess or difficult to access the target cardiac chamber
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A patient requiring a cardiac ablation for SVT with CHD
Device: Cardiac ablation using the MAGiC Ablation Catheter
This MAGiC ablation catheter is used the the robotic Magnetic System to perform an ablation in a patient who has a SVT. Other patients who are not participaing in this study may have the same proceudre, the procedure with a different catheter, a procedure with a manual catheter, drug therapy or no treatment
Acute Success
Non-indcability of Supraventricular Tachycardia (SVT)
Time frame: Peri-procedural
Chronic Success
subjects free from the treated index arrhythmia through 6 months post procedure. To be counted as recurrence, the recurrent arrhythmia must be the same arrhythmia as primary index arrhythmia and must last at least 30 seconds on Holter monitor or event monitor recording, OR present on the entirety of a 12-lead ECG (minimum recording duration of 10 seconds) OR documented on a personal ECG device recording of a minimum of 30 seconds duration.
Time frame: 6 months
Acute Safety - Device or peocedure related adverse events
Device or procedure related serioius adverse events which occurred prior to 7 days post-procedure
Time frame: 7 days post procedure
Serious device related events
All serious device related adverse events
Time frame: 6 months
Acute & Chronic Success
Estimating acute procedural success and chronic success by type of target arrhythmia and by specific congenital defect and surgical repair.
Time frame: 6 months
Procedure time
Characterize procedure time from insertion of first sheath to removal of last sheath
Time frame: Peri-procedural
Fluoroscopy Duration
Review of Fluoroscopy duration
Time frame: Peri-procedural
Hospitlization
Estimate the percentage of subjects free from the treated index arrhythmia or procedure related hospitalizations and major adverse events
Time frame: 6 months
Serious Advere Events
Estimate the rate of subjects experiencing serious adverse events by event
Time frame: 6 months
Quality of Life and arrhythmia burden
Estimate the change in subject quality of life and arrhythmia burden. Each question on the form is scored individually and a decreasein values would be considered that the pateint is doing better. The range for each question is from 0-8 or 0-9 dependng in the question
Time frame: 6 months
Unmet medical need
Compilation of the anatomical and clinical challenges unique to the subject population, usage of the MAGiC catheter to address these challenges, and qualitative commentary on performance of MAGiC.
Time frame: Peri-procedural
Fluoroscopy Dose
Review of the dose of DAP used during the procedure
Time frame: Peri-procedural
No study locations are listed for this record.
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tachycardia, Supraventricular →
Stereotaxis